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A brief review of the neurochemical effects of the convulsant agent L-methionine-df-sulfoximine (MSO) on  cerebral 
methylation reactions is presented. Our findings point  to t h e  involvement of a number of endogenous methyl acceptor 
molecules, including histamine, membrane phospholipids, and membrane proteins, in the  mediation of the convulsant 
effect. Our findings also associate the inhibition of methylations by high levels of S-adenosyl-L-homocysteine in  brain 
with protection against MSO-induced seizures. We propose that MSO acts by eliciting t h e  acceleration of  a regulatory 
methylation-demethylation sequence at key molecular sites, including the  benzodiazepine receptor complex, which 
creates an imbalance i n  this sequence’s normal mediation of convulsant-anticonvulsant mechanisms. 
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In our epilepsy-related research, we have been inves- 
tigating the mechanism of action of the long-latency 
chemical convulsant agent L-methionine-dl-sulfoximine 
(MSO), which is the neurotoxic factor in nitrogen tri- 
chloride-treated wheat gluten and in the resulting 
canine hysteria 1 1 ,  23, 241. Because of the similarity of 
MSO-induced convulsions in animals to those of hu- 
man epilepsy 117, 21, 221, this agent has been the 
object of numerous physiological and biochemical in- 
vestigations (see [45] for review). 
Biochemical studies have explored the effects of 
MSO on cerebral glutamate, glutamine, and y- 
aminobutyric acid metabolism 18, 9,2O, 25 ,29 ,  36, 38, 
41 ,  421, biogenic amines 12, 6, 28, 371, cyclic nucleo- 
tides 112, 131, ammonia [lo, 14, 18, 27, 441, and poly- 
amines [26}. 
In addition, in 1975 we reported that the in- 
traperitoneal administration of MSO to rats resulted 
in a significant decrease in the level of cerebral 
3-adenosyl-L-methionine (AdoMet), the universal 
methyl donor molecule [3  13. We subsequently showed 
that this decrease is not the result of a reduced biosyn- 
thesis of AdoMet 1351, but rather, it is a consequence 
of an overall increase in the utilization of AdoMet that 
sets in about halfway through the 5- to 6-hour MSO 
preconvulsant period [30, 321. Obversely, we also 
showed that higher than normal levels of brain S- 
adenosyl-L-homocysteine (AdoHcy), the demethylated 
product of AdoMet and a potent inhibitor of cellular 
transmethylations, are associated with significant antag- 
onism to the action of MSO. 
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In the present report, the effects in the mouse of a 
convulsant dose of MSO, which results in an increase 
in cerebral methylations, are contrasted with the effects 
of a joint administration of adenosine and DL-homo- 
cysteine thiolactone (Ado + HcyT), a treatment that 
results in extremely high AdoHcy levels in brain [341, 
significant inhibition of cerebral methylations [3  3, 341, 
and protection against MSO seizures. 
Methods 
Mice were injected intraperitoneally with MSO and with 
Ado + HcyT at the doses indicated in Figures 1 to 4 and 
Tables 1 to 4. In experiments in which the specific radioac- 
tivities of brain methionine, AdoMet, and AdoHcy were 
to be determined, carbon 14-labeled methionine ([ 1-‘4C] 
methionine) was used, while in experiments in which the 
in vivo phospholipid and carboxyl methylation of proteins 
was to be determined, tritium-labeled methyl methionine 
([methyl-3H]methionine) was used. [3,4-”CCfMethionine was 
used as the precursor of polyamines. The radioactively 
labeled methionine and [2,5-3H]histamine were injected in- 
traventricularly while the animals were under light ether 
anesthesia. 
The specific radioactivity values of methionine, AdoMet, 
and AdoHcy were determined by the procedure of Schatz 
and colleagues [34f, those of methyl histamine were deter- 
mined by the procedure of Schatz and colleagues [30], and 
those of the polyamines were determined by the procedure 
of Porta and colleagues E26). In vivo phospholipid methyla- 
tion was determined by the procedure of Hirata and col- 
leagues [lb], as modified by Schatz and colleagues 1331. 
while in vivo protein carboxyl methylation was quantitated by 
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Fig  I. Effect of L-methionine-dl-sulfoximine (MSO) on the 
specific radioactivity of (A) methionine, (B) S-adenosyl-L- 
methionine, and (C) S-adenosyl-L-homocysteine in  mouse brain. 
Mice were injected intraperitoneully with saline (10 mllkd or 
MSO ( 1  50 mglkgi 180 minutes prior to  killings. Carbon 14- 
labeled methionine (2 pCill0 p l  of artificial CerebrospinalfEuid) 
was injected into the lateral cerebral ventricle 10, 30, 60, 120, 
and 180 minutes prior to  killing. Speclfic radioactivity values are 
expressed in  disintegrations per minute (dpm) x 10- ' per 
nanomole as means * SEM in from 5 t o  7 mice. Open symbols 
denote values signi$cant(y different from corresponding controls at 
the 0.05 level using Student? t test (two-tailed). 
the procedure of Kim 1191, as modified by Schatz and col- 
leagues [331. 
Results 
The specific radioactivity of [ 14C)methionine was in- 
creased 52 to 120% in MSO-treated mice (Fig 1A). 
This increase could not be offset by the 25% decrease 
in endogenous methionine levels noted after MSO 
administration (data not shown). Conversely, the ad- 
ministration of Ado +- HcyT resulted in increases in 
endogenous methionine (data not shown) and in 
{ 14C}methionine specific radioactivity values that were 
of similar magnitude (28 to 34%). The [l*C]AdoMet 
specific radioactivity values after MSO administration 
(Fig 1B) were significantly elevated, whereas they re- 
mained unchanged after Ado + HcyT administration 
(Table I). The MSO and Ado + HcyT treatments had 
opposite effects on the specific radioactivity values of 
cerebral AdoHcy, as illustrated by the relevant data in 
Figure 1C and Table 1, respectively. Table 2 shows that 
MSO administration increased the rate of conversion 
of cerebral histamine to its single metabolite, methyl 
histamine, while Ado + HcyT administration de- 
creased this conversion rate. 
Similarly, Table 3 illustrates the opposite effects 
of MSO and Ado + HcyT on the conversion of 
methionine (through AdoMet and decarboxylated 
AdoMet) to the cerebral polyamines spermidine and 
spermine. Cerebral phospholipid methylation was 
selectively and differentially affected by the MSO and 
Ado + HcyT treatments, as illustrated in Figure 2. 
Protein carboxyl methylation was also significantly 
increased (90%) after MSO administration and was 
significantly decreased after Ado + HcyT administra- 
tion (Fig 3). Most recently, we also found that in rat 
brain, the MSO treatment increases the carboxyl 
methylation of proteins contained in a detergent- 
solubilized membrane fraction that also contains ben- 
zodiazepine receptor proteins (Sellinger OZ, Gregor 
P: unpublished observations, 1983) (Table 4). 
Finally, we established that treatment of mice with 
Ado + HcyT increases the MSO seizure latency pe- 
riod. The maximal (80%) increase occurred in mice 
with markedly elevated AdoHcy levels in brain (Fig 4). 
Table 1. Effect of Ado + HcyT on the Specific Radioactivity of Methionine, AdoMet, and AdoHcy in Mouse Brain" 
Experimental Group Methionine AdoMet AdoHcy 
Control 5.94 ? 0.59 5.53 ? 0.27 2.18 t 0.31 
Ado + HcyT (200 mg/kg, 40 min prior to killing) 7.94 +- 0.82h 5.88 ? 0.39 0.72 f 0.05' 
"The values are in disintegrations per minute x 10- per nanomole (mean t SEM). There were 7 animals per group. Two microcuries of carbon 
14-labeled rnethionine was given to each animal intraventricularly 1 hour prior to killing. 
' p  < 0.05. 
' p  < 0,001. 
Ado + HcyT = adenosine + DL-hornocysteine thiolactone; AdoMet = S-adenosyl-L-merhionine; AdoHcy = S-adenosyl-L-homocysteine. 
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Table 2 .  Effects of MSO and Ado + HyT 
on the Methyl Histamine Conversion Index in  Mouse Brain 
Conversion 
Index 
Experiment" (nmoUgm)b 9Z Change 
EXPERIMENT 1 
Control 2.2 
MSO (170 mgikg, 3 hr 4.5 + 105 
prior to killing) 
EXPERIMENT 2 
Control 7.3 
Ado + HcyT (200 mglkg, 2.5 - 66 
40 min prior to killing) 
"Two microcuries of [2,5-3H)histamine (specific activity, 7.7 Ci/ 
mmol) was injected intraventricularly in each animal, 15 and 5 min- 
utes before killing, in Experiments 1 and 2, respectively. 
bDisintegrations per minute per gram of tritium-labeled methyl his- 
tamine (Irneth~l-~Hlhistamine) divided by disintegrations per minute 
per nanomole of {3H]histamine. 
MSO = L-methionine-dhulfoximine; Ado + HcyT = adenosine + 
DL-homocysreine thiolacrone. 
Discussion 
One assumption guiding the interpretation of the re- 
sults depicted in Figure 1 is that intraventricularly ad- 
ministered {'*C]methionine mixed with endogenous 
me thionine. The higher-than-control specific radioac- 
tivity values of methionine (see Fig 1A) suggest that 
this increase occurred despite a partial decrease in en- 
dogenous methionine levels (data not shown). A likely 
explanation of the increased specific radioactivity val- 
ues of AdoMet and AdoHcy in brains of the MSO- 
treated mice (see Fig lB, C )  is that the methionine 
was derived from a "hotter" pool than the control 
" I PME PMME PC 
Fig  2. Effects of L-methionine-dl-su&oximine (MSO) and 
adenosine + DL-homoysteine thiolactone (Ado + HcyT) on 
brain phospholipid methylation. Mice were injected in- 
traperitoneally with saline (1 0 mllkd or MSO (1 SO mgikd 180 
minutes prior t o  killing, while Ado + HcyT (200 mglkgi or 
saline and polysorbate 80 (20 mllkgi was injected intraperitone- 
ally 40 minutes prior to killing. Tritium-labeled methyl 
methionine (5 pCill0 p! of artificial cerebrospinaljuid) was in- 
jected into the lateral cerebral ventricle 60 minutes prior to  kill- 
ing. Values are expressed as means * Jtandard error of the mean 
(indicated by the height of the single vertical line.( on the bars) in  
6 or 7 mice. Asteriskr denote vahes signifcant& diflerent from 
values in control mice at the 0.05 level using Student's t test (two- 
tailed). DPM = disintegrations per minute; PME = {'H} 
phosphatidylmonomethylethanolamine; PMME = {iH]phos- 
phatidyldimethylethanolamine; PC = {'H)phosphatidylcboline. 
pool. The finding that the specific radioactivity of 
AdoMet peaked at 30 minutes in both control and 
MSO-treated brains (see Fig lB), while that of 
AdoHcy peaked at 30 minutes in the MSO-treated 
brains but at 60 minutes in the control brains, is con- 
sistent with the premise that the overall Aw of 
methionine through the transmethylation and poly- 
mine-formation pathways of brain accelerates in the 
brains of MSO-treated mice. 
Table 3. Efects o f  MSO and Ado t- HcyT on the Conversion o f  {3,4-14C}Methionine 
to {14C}Spemidine and {'4C}Spemine in  Mouse Brain 
Experiment 
[ 14C)Spermidine ["~l~per rn ine  
(dpdnmol) (dpmhmol) 
EXPERIMENT 1" 
Control 28.4 ? 1.0 ( 7 )  40.1 5 1.2 ( 7 )  
MSO (150 mglkg, 3 hr prior to killing) 60.6 2 4.3 ( I l ) d  42.7 ? 3.9 (11)c 
EXPERIMENT zb  
Control 12.3 ? 0.7 (6)  16.8 0.9 (6)  
Ado + HcyT (500 mg/kg, 40 min prior to killing) 13.0 5 1.19 (6)' 8.84 ? 0.67 (6)' 
"Two microcuries of carbon 14-labeled methionine (["C]methionine) was injected intraventricularly. 
' p  < 0.005. 
' p  < 0.05. 
N.B.: The pulse time was 1 hour in both experiments. Values are mean 2 SEM. 
MSO = L-methionine-dl-sulfoximine; Ado + HcyT = adenosine + DL-homocysteine thiolactone; dpm = disintegrations per minute 
microcurie of [ '*C]methionine was injected intraventricularly. 
d p  < 0.001. 





F i g  3. Ejjects of L-methionine-dl-sulimine (MSO) and 
adenosine + DL-homocysteine thiolactone (Ado + HcyT) on in 
vivo brain protein carboxyl methylation. (For details of drug 
treatment. expression of results, statistical analysis, and 
Ahnitton of terms see Figure 2.) 
Table 4. Effect of MSO on the In Vivo 
Curboxyl Methylation of Rat Brain Proteins 
Experimental - 
Group dprn dpmlrng dpm 9% H dpmlmg 
Homogenate Soluble 
Control 30,400 294 980 3.2 260 
MSO 33,300 445 1,430 4.3 591 
MSOkontrol 1.10 1.5 2 1.46 . . . 2.27 
N.B.: MSO (150 mg'kg) was injected intraperitoneally, and tritium- 
labeled methyl methronine ( [rne th~l -~H] methionine) (specific activ- 
ity, 8 Cdmmol) contaming 18.7 pCi of radioactivity per gram of brain 
was injected intraventricularly 2 hours later. One hour after the 
intraventricular injection, the brains of the 26-day-old rats containing 
18.7 pCi of radioactivity per gram of brain were homogenized indi- 
vidually (4 controls and 4 MSO-treated) by means of the Polytron 
homogenizer (Brinkmann Instruments) in 10 mM sodium phosphate 
buffer containing 0.2 hl sodium chloride, at p H  6.8. The crude 
membrane fraction was prepared according to Burch and Ticku [3]. 
The membrane pellet was suspended in buffer containing 1% 
Lubrol-Px (Sigma products; L = 37531, and after 30 minutes at 4"C, 
the suspension was centrifuged for 45 minutes at 100,000 g. The 
clear supernatant was dialyzed against buffer for approximately 12 
hours at 4"C, yielding the soluble fraction, which contained the 
solubilized benzodiazepine receptor complex. 
H = homogenate; MSO = L-methionine-dl-sulfoximine; dpm = 
disintegrations per minute. 
It should be noted that these interpretations are 
still not conclusive, given the metabolic and dynamic 
complexities of the biochemical pathways involving 
methionine in cerebral tissue. Our failure to measure 
the extent of the recycling of cerebral homocysteine 
back to methionine under the prevailing experimental 
conditions further biases the purely quantitative as- 
pects of the findings. In our estimation, however, the 
diametrically opposite qualitative effects of MSO and 
Ado + HcyT are sufficiently documented so as to be 
of physiological validity in the convulsant context 
within which they were obtained. 
Since the ability of MSO to elicit seizures presum- 
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F i g  4. Effect of adenosine i- DL-hornocysteine thiolactone (Ado 
+ HcyT) on 5-adenosyl-~-homocysteine (AdoHcy) let& and L- 
methionine-dl-suFoximine (MSO) seizure lutency. M i a  were in- 
jected intraperitoneally with MSO (125 mglkg), afer which .sei- 
zure latency was determined (top panel, open bar). Animals not 
convulsing within 8 hours were arbitrarily assigned a seizure la- 
tency of 480 minutes. Another group of mice received MSO 180 
minutes prior t o  killing, after which the AdoHcy levels in brain 
were determined (bottom panel, open bar). Mice were also injected 
with MSO followed by Ado f HcyT, at the times indicated fol- 
lowing MSO administration, ufter which either seizure latency 
values (top panel, closed bars) o r  AdoHcy levels (bottom panel, 
closed bars) were determined. Values are expressed in minutes (top 
panel) o r  in percentage changes (bottom panel) us means +- SEM 
in 8 mice. Stars denote values significant(y different from  value.^ 
in mice treated with MSO only (open bars) using Student's t tedt 
(two-tailed) at the 0.05 leiel. 
ably involves neural membranes, it was of interest to 
examine the effects of MSO and Ado + HcyT on the 
methylation of some membrane components. The in- 
crease in ~3H]phosphatidylmonornethylethanolamine 
(C3H]PME) levels after MSO administration (see Fig 
2) reflects increased phospholipid methyltransferase I 
(PMT I) activity and increased synthesis of PME, a 
normal constituent of brain 1371. It has been proposed 
that the methylation of phosphatidylethanolamine (PE) 
to PME is the initiating event in decreasing membrane 
microviscosity [15]; hence the increase in C3H]PME 
after MSO administration may reflect increased mem- 
brane fluidity. This may further indicate that cerebral 
membranes become labile, or more apt to promote 
impulse firing in the MSO-treated brain than in the 
normal brain. Conversely, treatment with Ado + 
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HcyT inhibited the formation of [3H}phosphatidyl- 
dimethylethanolamine (r3H1PMME) and [3H1phos- 
phatidylcholine (C3HIPC) without altering I3H)PME 
levels 1331 (see Fig 2). The lack of an effect on E3H}- 
PME may be related to the fact that membranes are 
relatively impermeable to AdoHcy [7, 34,431 and thus 
prevent access to the PMT I located on the cytoplasmic 
side of the cell membrane [4, 5 ,  1 5 ,  351. Conversely, 
the Ado + HcyT-induced decrease in 13H)PMME 
and E3H]PC reflects inhibition of the enzyme PMT I1 
located on the outside of the synaptosomal membrane 
[4,  5 1  and therefore readily accessible to external Ado- 
Hcy, which is known to bind to brain membranes Ill}. 
The stimulation of particulate protein carboxyl 
methylation after MSO administration (see Fig 3 )  fur- 
ther supports the hypothesis that membrane function 
may be altered during MSO-induced epileptogenesis. 
The marked inhibition of this process after Ado + 
HcyT administration (see Fig 3 )  agrees with this prem- 
ise. Additional evidence that MSO may alter mem- 
brane function is provided by the recent finding that 
(Na+ + K+ )-adenosinetriphosphatase activity in brain 
is increased after MSO administration [40} and by our 
preliminary results on the enhancing effects of MSO 
on the carboxyl methylation of synaptic membrane 
proteins (Sellinger 02, Gregor P: unpublished obser- 
vations, 1983). 
The administration of Ado + HcyT also greatly in- 
creased the latency period to MSO-induced seizures 
and decreased their incidence (see Fig 4). The finding 
that this protective effect was greatest when AdoHcy 
levels in brain were markedly elevated further supports 
the concept that it is the ensuing inhibition of brain 
transmethylations that mediates this effect. 
The bulk of the findings presented in this paper thus 
tend to be in support of the principal premise that 
motivated our research, namely, that the convulsant 
action of MSO is mediated by the hypermechylation of 
a variety of cerebral methyl acceptor molecules. Work 
is in progress to determine whether benzodiazepine 
receptor proteins are the molecular mediators of this 
convulsant-anticonvulsant process, via a mechanism of 
on-and-off carboxyl methylation and demethylation in- 
volving their glutamate and aspartate residues. 
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